Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): Therapeutic implications

Oncogene

Volumn 19, Issue 3, 2000, Pages 395-402

  Chu, Wendy ^a   Pak, Brian J ^a   Bani, Maria Rosa ^a,b   Kapoor, Monika ^a   Lu, Shi Jiang ^a,c   Tamir, Ami ^a   Kerbel, Robert S ^a   Yaacov, Ben David ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

^c MICHAEL REESE HOSPITAL   (United States)

Author keywords

Chemotherapy; cis diamminedichloroplatinuim(II); Drug resistance; Malignant melanoma; Tyrosinase related protein 2

Indexed keywords

CARBOPLATIN; CISPLATIN; METHOTREXATE; PACLITAXEL; TYROSINASE RELATED PROTEIN 2;

APOPTOSIS; ARTICLE; CELL CLONE; CELL LINE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG RESISTANCE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; NORTHERN BLOTTING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 0034688176     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1203315     Document Type: Article

References (41)

1. Andrews PA, Murphy MP and Howell SB. (1985). Cancer Res., 45, 6250-6253.
2. Aroca P, Garcia-Borron JC, Solano F and Lozano JA. (1990). Biochim. Biophys. Acta., 1035, 266-275.
3. Balch CM, Houston A and Peter L. (1989). Cutaneous melanoma. In: Cancer: Principles and Practices of Oncology. 3rd edn. De Vita VT, Hellman S and Rosenberg SA. (eds). Lippincott: Philadelphia, pp 1499-1542.
4. Bartholomew C, Morishita K, Askew D, Buchberg A, Jenkins NA, Copeland NG and Ihle JN. (1989). Oncogene, 4, 529-534.
5. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE and Cowan KH. (1986). J. Biol. Chem., 261, 15544-15549.
6. Bernd A, Ramirez-Bosca A, Kippenberger S, Martinez-Liarte JH, Holzmann H and Solano F. (1994). Melanoma Res., 4, 287-291.
7. Borchers AH, Kennedy DA and Straw JA. (1990). Cancer Res., 50, 1786-1789.
8. Chan HS, Lu Y, Grogan TM, Haddad G, Hipfner DR, Cole SP, Deeley RG, Ling V and Gallie BL. (1997). Cancer Res., 57, 2325-2330.
9. Chu G. (1994). J. Biol. Chem., 269, 787-790.
10. Chu G and Chang E. (1990). Proc. Natl. Acad. Sci. USA, 87, 3324-3327.
11. Citro G, D'Agnano I, Leonetti C, Perini R, Bucci B, Zon G, Calabretta B and Zupi G. (1998). Cancer Res., 58, 283-289.
12. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM and Deeley RG. (1992). Science, 258, 1650-1654.
13. Dolan ME, McRae BL, Ferries-Rowe E, Belanich M, van Seventer GA, Guitart J, Pezen D, Kuzel TM, Yarosh DB. (1999). Clin. Cancer Res., 5, 2059-2064.
14. Fillpits M, Suchomel RW, Dekan G, Stiglbauer W, Haider K, Depisch D and Pirker R. (1997). Br. J. Cancer, 75, 208-212.
15. Ho RCS. (1995). Cancer, 75, 735-741.
16. Ishikawa T, Wright CD and Ishizuka H. (1994). J. Biol. Chem., 269, 29085-29093.
17. Jackson IJ, Chambers DM, Tsukamoto K, Copeland NG, Gilbert DJ, Jenkins NA and Hearing V. (1992). EMBO J., 11, 527-535.
18. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, Wolff K, Eichler HG and Pehamberger H. (1998). Nat. Med., 4, 232-234.
19. Kartner N, Everden-Portelle D, Bradley G and Ling V. (1986). Nature, 316, 820-823.
20. Kawakami Y, Robbins PF, Wang RF, Parkhurst M, Kang X and Rosenberg SA. (1998). J. Immunother., 21, 237-246.
21. Koo HM, Gray-Goodrich M, Kohlhagen G, McWilliams MJ, Jeffers M, Vaigro-Wolff A, Alvord WG, Monks A, Paull KD, Pommier Y and Vande Woude GF. (1999). J. Natl. Cancer Inst., 91, 236-244.
22. Kung HJ, Boerkoel C and Carter TH. (1991). Curr. Top. Microbiol. Immunol., 171, 1-25.
23. Kuroda H, Sugimoto T, Ueda K, Tsuchida S, Horii Y, Inazawa J, Sato K and Sawada T. (1991). Int. J. Cancer, 47, 732-737.
24. Lai G-M, Ozols RF, Smyth JF, Young RC and Hamilton TC. (1988). Biochem. Pharm., 37, 4597-4600.
25. Lai GM, Ozols RF, Young RC and Hamilton TC. (1989). J. Natl. Cancer Inst., 81, 535-539.
26. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG and Earnshaw WC. (1994). Nature, 371, 346-347.
27. Legrand O, Simonin G, Zittoun R and Marie JP. (1998). Leukemia, 12, 1327-1328.
28. Leonard LJ, Townsend D and King RA. (1988). Biochemistry, 27, 6156-6159.
29. Lorico A, Toffoli G, Boiocchi M, Erba E, Broggini M, Rappa G and D'Incalci M. (1988). Cancer Res., 48, 2036-2041.
30. Lu SJ, Man S, Bani MR, Adachi D, Hawley RG, Kerbel RS and Ben-David Y. (1995). Cancer Res., 55, 1139-1145.
31. Miyake H, Hanada N, Nakamura H, Kagawa S, Fujiwara T, Hara I, Eto H, Gohji K, Arakawa S, Kamidono S and Saya H. (1998). Oncogene, 16, 933-943.
32. Moriwaki S, Nishigori C, Takebe H, Imamura S. (1992). J. Dermatol. Sci., 4, 6-10.
33. Orlow SJ, Hearing VJ, Sakai C, Urabe K, Zhou BK, Silvers WK and Mintz B. (1995). Proc. Natl. Acad. Sci. USA, 92, 10152-10156.
34. Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA and Restifo NP. (1999). Proc. Natl. Acad. Sci. USA, 96, 2982-2987.
35. Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA and Kawakami Y. (1998). Cancer Res., 58, 4895-4901.
36. Pawelek JM. (1990). Biochem. Biophys. Res. Commun., 166, 1328-1333.
37. Peters G, Lee AE and Dickson C. (1986). Nature, 320, 628-631.
38. Tief K, Schmidt A and Beermann F. (1998). Brain Res. Mol. Brain Res., 53, 307-310.
39. Tsukamoto K, Jackson IJ, Urabe K, Montague PM and Hearing VJ. (1992). EMBO J., 11, 519-526.
40. Young RC. (1989). Drug resistance: The clinical problem. In: Drug Resistance in Cancer Therapy. Kluwer Academic Press: Philadelphia.
41. Zhen W, Link CJ, O'Connor PM, Reed E, Parker R, Howell SB and Bohr VA. (1992). Mol. Cell. Biol., 12, 3689-3698.